OleanderPhoenix Biotechnology executes a seventh amendment to its Sponsored Research Agreement with M. D. Anderson Cancer Center. Posted on January 2012June 2022 by Carlos Torres 06 Jan Phoenix Biotechnology enters into a research agreement with Rational Therapeutics, Inc. to conduct examination of antitumor effects of PBI-05204 on human tumor biopsy samples (an ‘in vitro’ Phase II study). Research Article: Cardiac glycosides exert anticancer effects by inducing immunogenic cell death.
